111 YI Revenue Breakdown

NASDAQ YI
$2.84 -0.01 (-0.35%)
As of: Nov 16, 2026 · 3:46 PM EST
Annual revenue breakdowns for 111, fiscal 2016 to 2025, as reported in its filings.
Annual history

111 Revenue by Product & Service

Years FY 2016–2025
Lines 6
FY 2025 Total $12.56B

Drugs was 111’s largest product and service line in fiscal 2025, bringing in $11.65B of $12.56B (93%).

111 revenue by product and service, fiscal 2016 to 2025
Product and Service FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Drugs $12.57B $13.88B $13.40B $11.65B
Nutritional Supplements $554.79M $631.12M $550.46M $434.69M
Medical Supplies & Devices $164.92M $157.50M $144.28M $152.35M
Other Products $111.10M $170.23M $201.83M $233.69M
Mp Service $68.48M $70.27M $65.54M $56.75M
Other Services $44.79M $35.95M $40.97M $28.63M
Total $13.52B $14.95B $14.40B $12.56B
Totals include 1 discontinued line from earlier reporting.

111 revenue by product and service: what the figures show

111 brought in $12.56B from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 12.8% from $14.40B in fiscal 2024. Drugs was the largest at $11.65B (92.8%), ahead of Nutritional Supplements at $434.69M (3.5%) and Other Products at $233.69M (1.9%). The other three lines brought in $237.73M combined.

Compared with fiscal 2024, Drugs fell 13.0% to $11.65B and Nutritional Supplements fell 21.0% to $434.69M. From fiscal 2022 to 2025, combined revenue from these lines fell from $13.52B to $12.56B, a compound annual decline of 2.4%. Drugs' share held steady at about 92.8%.

Annual history

111 Revenue by Segment

Years FY 2016–2025
Lines 2
FY 2025 Total $12.56B

B2B Segment was 111’s largest segment in fiscal 2025, bringing in $12.32B of $12.56B (98%).

111 revenue by segment, fiscal 2016 to 2025
Segment FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
B2B Segment $13.08B $14.57B $14.12B $12.32B
B2C Segment $441.53M $377.36M $278.10M $234.82M
Total $13.52B $14.95B $14.40B $12.56B

111 revenue by segment: what the figures show

111 brought in $12.56B from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 12.8% from $14.40B in fiscal 2024. B2B Segment was the largest at $12.32B (98.1%), ahead of B2C Segment at $234.82M (1.9%).

From fiscal 2022 to 2025, combined revenue from these segments fell from $13.52B to $12.56B, a compound annual decline of 2.4%. B2B Segment's share of the total rose from 96.7% to 98.1%.

Questions

111 Revenue Breakdown FAQ

How does 111 make money?

111 (YI) reports its revenue by product and service and by segment. In fiscal 2025, Drugs was its largest product and service line, bringing in $11.65B (92.8% of the total), followed by Nutritional Supplements at $434.69M (3.5%).

What is 111's largest product and service line?

Drugs was 111's largest product and service line in fiscal 2025, bringing in $11.65B, or 92.8% of the $12.56B total across its six product and service lines.

What is 111's largest segment?

B2B Segment was 111's largest segment in fiscal 2025, bringing in $12.32B, or 98.1% of the $12.56B total across its two segments.

Where does this revenue breakdown data come from?

Every figure comes from 111's annual financial filings, as reported. Each line keeps the name 111 gives it, and years follow its fiscal calendar.

How far back does 111's revenue breakdown go?

111's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.